# Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

> **NCT01234402** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 153 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** Ramucirumab DP
- **BIOLOGICAL:** IMC-18F1
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01234402
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-10
- **Final completion:** 2017-07
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2019-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01234402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01234402, "Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01234402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*